2018 didn't shape up exactly the way he had imagined, but Echelon Wealth Partners analyst Doug Loe thinks 2019 could be Profound Medical's (Profound … [Read more...] about Profound Medical is an undervalued life sciences stock for 2019, Echelon says
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Mackie Research maintains “Hold” rating on Theratechnologies
Positive new data for Theratechnologies' (Theratechnologies Stock Quote, Chart TSX:TH) HIV treatment Trogarzo isn't moving the needle for Mackie … [Read more...] about Mackie Research maintains “Hold” rating on Theratechnologies
Profound Medical is a breakout biotech stock for 2019, Paradigm Capital says
Ahead of the company's fourth quarter results, Paradigm Capital analyst Rahul Sarugaser is more than bullish on Profound Medical Corp. (Profound … [Read more...] about Profound Medical is a breakout biotech stock for 2019, Paradigm Capital says
Buy Kalytera Therapeutics for a 328 per cent return: Echelon Wealth
California-based drug developer Kalytera Therapeutics (Kalytera Therapeutics Stock Quote, Chart TSXV:KALY) may be facing competitive headwinds going … [Read more...] about Buy Kalytera Therapeutics for a 328 per cent return: Echelon Wealth
Zymeworks has lots of upside, Paradigm Capital says
Paradigm Capital analyst Rahul Sarugaser is expecting 2019 to be a big clinical year for Zymeworks (Zymeworks Stock Quote, Chart NYSE:ZYME) In … [Read more...] about Zymeworks has lots of upside, Paradigm Capital says
Treosulfan brings diversity to Medexus Pharma, Mackie Research says
After being granted Health Canada approval to distribute Treosulfan, a conditioning agent used prior to stem cell transplantations, Mackie Research … [Read more...] about Treosulfan brings diversity to Medexus Pharma, Mackie Research says
Take a pass on Extendicare, says Echelon Wealth
Softness in its home healthcare and nursing home operations are cause for a rating change for Extendicare (Extendicare Stock Quote, Chart TSX:EXE), … [Read more...] about Take a pass on Extendicare, says Echelon Wealth
Low testosterone treatment Natesto driving Acerus Pharma growth, Mackie Research says
Following the company's fourth quarter results, Mackie Research Capital analyst André Uddin remains bullish on Acerus Pharmaceuticals (Acerus … [Read more...] about Low testosterone treatment Natesto driving Acerus Pharma growth, Mackie Research says
Medexus Pharmaceuticals has a 149 per cent upside, Mackie Research says
Specialty pharma company Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, Chart TSXV:MDP) has announced a deal for the Canadian marketing … [Read more...] about Medexus Pharmaceuticals has a 149 per cent upside, Mackie Research says
Viemed Healthcare gets price target raise at Beacon Securities
Beacon Securities analyst Doug Cooper says growth may be accelerating for Viemed Healthcare (Viemed Healthcare Stock Quote, Chart TSX:VMD), who just … [Read more...] about Viemed Healthcare gets price target raise at Beacon Securities
